The European Tribune is a forum for thoughtful dialogue of European and international issues. You are invited to post comments and your own articles.
Please REGISTER to post.
Covid-19 vaccine candidate: Novasep signs a Master Supply and Development Agreement with AstraZeneca | Novasep - Nov. 12, 2020 | Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce that it has now signed a multi-year Master Supply and Development Agreement with AstraZeneca to support large-scale production of the active substance of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222. This new contract follows the initial agreement signed between AstraZeneca and Novasep Belgium on June 14th in the context of the Inclusive Alliance for Vaccines (IAV), whose members are France, Germany, Italy and the Netherlands. [Who was late at the table BoJo? ... honor British commitments] The production of the vaccine candidate active substance under this supply agreement will be carried out at Novasep's site located in Seneffe, Belgium which expects to increase its workforce from 280 to close to 400 by 2021 to support this project.
Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce that it has now signed a multi-year Master Supply and Development Agreement with AstraZeneca to support large-scale production of the active substance of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222.
This new contract follows the initial agreement signed between AstraZeneca and Novasep Belgium on June 14th in the context of the Inclusive Alliance for Vaccines (IAV), whose members are France, Germany, Italy and the Netherlands. [Who was late at the table BoJo? ... honor British commitments]
The production of the vaccine candidate active substance under this supply agreement will be carried out at Novasep's site located in Seneffe, Belgium which expects to increase its workforce from 280 to close to 400 by 2021 to support this project.
AstraZeneca COVID-19 Vaccine (AZD1222) Distribution On December 8, 2020, Halix B.V. announced it would provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. HALIX expands with 2 additional viral vector production lines to meet the increased demand.
On December 8, 2020, Halix B.V. announced it would provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. HALIX expands with 2 additional viral vector production lines to meet the increased demand.
Halix - Excellence in GMP Manufacturing
The 6,700 m2 BSL2 GMP facility, recently approved by the Dutch authorities and located on the Leiden Bio Science Park in the Netherlands, provides both clinical and commercial scale manufacturing capabilities in fully independent, self-contained Grade B and C cleanrooms for virus products.
by Luis de Sousa - Feb 28 1 comment
by IdiotSavant - Feb 28
by Oui - Mar 1 1 comment
by Frank Schnittger - Feb 23 15 comments
by Oui - Feb 22 19 comments
by Oui - Feb 25
by Frank Schnittger - Feb 20 16 comments
by gmoke - Feb 14 2 comments
by Oui - Mar 11 comment
by gmoke - Mar 1
by Luis de Sousa - Feb 281 comment
by Oui - Feb 2827 comments
by Frank Schnittger - Feb 2315 comments
by Oui - Feb 2219 comments
by Frank Schnittger - Feb 2016 comments
by Oui - Feb 2021 comments
by Frank Schnittger - Feb 1914 comments
by Oui - Feb 197 comments
by Oui - Feb 18
by Oui - Feb 1787 comments
by Oui - Feb 168 comments
by Frank Schnittger - Feb 1523 comments
by gmoke - Feb 142 comments
by Frank Schnittger - Feb 1413 comments
by Oui - Feb 145 comments
by Oui - Feb 1245 comments